Quantcast

Latest International AIDS Vaccine Initiative Stories

2010-04-22 11:59:00

NEW YORK and GAITHERSBURG, Md., April 22 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI) and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement. Lentigen's technology relies on a synthetic version of a virus related to HIV that has been...

2010-03-30 06:00:00

SMYRNA, Ga., March 30 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA (US Food and Drug Administration) to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV (Human Immunodeficiency Virus). The company will begin a non-blinded study in HIV infected individuals who started...

2010-03-24 09:53:00

SEATTLE, March 24 /PRNewswire/ -- Clinic sites in 13 cities across the U.S. are looking for a total of 1,350 HIV-negative gay men to participate in the latest HIV vaccine study from the HIV Vaccine Trials Network (HVTN). And they're using social media to help reach these individuals where they are, which, these days, is increasingly online. The HVTN, internationally headquartered at Fred Hutchinson Cancer Research Center in Seattle, is running a series of ads on Facebook, seeking men...

2010-03-22 10:12:00

SMYRNA, Ga., March 22 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative HIV/AIDS vaccines, has engaged The Investor Relations Group ("IRG"), a thirteen-year-old, award-winning, corporate communications firm based in New York City, to serve as its investor relations and public relations agency. "GeoVax Labs has outlined several important initiatives for 2010, and we are confident that IRG will have a...

2010-03-01 08:00:00

ATLANTA, March 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company focused on development of HIV/AIDS vaccines, today announced its financial results for the fourth quarter and year ended December 31, 2009. GeoVax reported a net loss of $843,275 for the fourth quarter ended December 31, 2009, as compared to a net loss of $1,039,217 for the comparable period in 2008. For the full year of 2009, the Company reported a net loss of...

2010-02-02 07:00:00

ATLANTA, Feb. 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., president and chief executive officer, will present a corporate update at the 12th Annual BIO CEO & Investor Conference. The presentation will take place at 1:00 p.m. Eastern Time on...

2010-01-06 08:00:00

ATLANTA, Jan. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced the appointment of Mark J. Newman, Ph.D. as vice president, research and development. Dr. Newman will be responsible for developing GeoVax's therapeutic HIV vaccine initiative and broadening the GeoVax pipeline....

19bef4596657ecd3d5e0430451ff40661
2009-12-14 12:18:04

Researchers from Thomas Jefferson University are one step closer to developing a vaccine against the AIDS disease. Led by Matthias J. Schnell, Ph.D., director of the Jefferson Vaccine Center, the researchers found that a rabies virus"“based vaccine administered to monkeys protected against the simian equivalent of the HIV virus (SIV). The data were published in the journal Vaccine. The researchers previously showed that a rabies-based vaccine expressing HIV and SIV antigens protective...

2009-12-01 08:00:00

ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its support for World AIDS Day. "Today is the 21st World AIDS Day and as we remember the millions that have lost their fight with the HIV/AIDS pandemic, we remain focused and devoted to commercializing both...

2009-11-30 11:17:00

HARRISBURG, Pa., Nov. 30 /PRNewswire-USNewswire/ -- In recognition of World AIDS Day on Dec. 1, Department of Health Secretary Everette James today reminded Pennsylvanians to be tested regularly for HIV - the virus that causes AIDS. "Getting tested is the only way to know your health status and knowing your status is the only way to ensure you receive proper treatment," said James. "We are working to educate the public and ensure that prevention, testing, treatment and counseling services...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related